EuroPCR 2019 | TRILUMINATE: Reparación tricuspídea con clip mejora la insuficiencia y la calidad de vida

EuroPCR 2019 | TRILUMINATE: Tricuspid Repair with Clip Improves Regurgitation and Quality of Life

Transcatheter therapy offers a promise for a largely forgotten valve given the lack of therapeutic options. Percutaneous edge-to-edge repair with clip seems to offer some hope to patients with tricuspid regurgitation according to the TRILUMINATE. At 30 days, transcatheter repair with clip significantly reduced tricuspid regurgitation at least in one grade in most patients, which<a href="https://solaci.org/en/2019/05/24/europcr-2019-triluminate-tricuspid-repair-with-clip-improves-regurgitation-and-quality-of-life/" title="Read more" >...</a>

Reparación de la válvula tricúspide con la técnica del Mitra Clip

Promising Results for Tricuspid Repair

Courtesy of Dr. Carlos Fava. Tricuspid regurgitation (TR) is more common than we thought. Around 1.6 million people in the US and over 3 million in Europe experience significant TR. It usually has a functional cause and its negative impact on patient prognosis is strong.   Its surgical treatment is challenging, and it is important that its resolution<a href="https://solaci.org/en/2019/05/03/promising-results-for-tricuspid-repair/" title="Read more" >...</a>

Cirugía para mejorar la sobrevida en insuficiencia tricuspidea aislada

Is Tricuspid Regurgitation after TAVR Significant?

Courtesy of Dr. Carlos Fava. Severe or moderate mitral regurgitation is associated to worse evolution after TAVR. However, we should not forget the tricuspid valve that, even though not extensively researched, is also associated to a negative impact in its evolution. A meta-analysis of 12 studies with a total 41485 patients was carried out. <a href="https://solaci.org/en/2019/04/16/is-tricuspid-regurgitation-after-tavr-significant/" title="Read more" >...</a>

TCT 2018 | TriValve: Mitraclip para la válvula tricúspide

TCT 2018 | TriValve: Mitraclip for the Tricuspid Valve

The TriValve is a multicenter, international and retrospective study of multiple devices for percutaneous intervention to treat cardiac failure. This is a sub-analysis of patients receiving the most conventional of these devices: the MitraClip. The main points assessed by this study were all cause mortality, unplanned hospitalizations, functional class, the presence of peripheral edema, and<a href="https://solaci.org/en/2018/10/08/tct-2018-trivalve-mitraclip-for-the-tricuspid-valve/" title="Read more" >...</a>

More Evidence For MitraClip in High Risk Patients with Severe Tricuspid Regurgitation

Courtesy of Dr. Carlos Fava. Tricuspid regurgitation (TR) has a negative impact in the long run. Several reports have shown that, in high risk inoperable patients, transcatheter edge-to-edge valve repair with MitraClip is feasible, safe and has good results, but there is still a long way to go. The present study looked at 24 consecutive<a href="https://solaci.org/en/2018/08/21/more-evidence-for-mitraclip-in-high-risk-patients-with-severe-tricuspid-regurgitation/" title="Read more" >...</a>

Treating Tricuspid and Mitral Valves with MitraClip Improves Quality of Life

Courtesy of Dr. Carlos Fava. It has been shown that significant tricuspid regurgitation (TR) is an independent predictor of bad evolution in the presence of mitral valve disease. Its prevalence is not low, reaching up to 50% in patients undergoing surgery for mitral regurgitation (MR). This study included 61 patients with significant TR and MR. 27<a href="https://solaci.org/en/2018/07/02/treating-tricuspid-and-mitral-valves-with-mitraclip-improves-quality-of-life/" title="Read more" >...</a>

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

Tricuspid Regurgitation: MitraClip Improves Survival

Courtesy of Dr. Carlos Fava. Tricuspid regurgitation (TR), both isolated or associated with other left valve diseases, has been associated with higher rates of heart failure hospitalization and of cardiovascular death. Recent studies in elderly high-risk patients who underwent percutaneous treatment of left valve disease have shown the presence of TR to be associated with<a href="https://solaci.org/en/2018/07/02/tricuspid-regurgitation-mitraclip-improves-survival/" title="Read more" >...</a>

Tricuspid and Bicuspid Valves Present More Coincidences Than Expected

There is more and more positive evidence that new-generation transcatheter valves, originally designed to treat tricuspid aortic valves, work perfectly fine on bicuspid aortic valves. A comparison of computerized tomography (CT) scans obtained before and after the procedure showed that the most commonly used devices appear to reshape the aortic annulus to the same degree<a href="https://solaci.org/en/2017/10/13/tricuspid-and-bicuspid-valves-present-more-coincidences-than-expected/" title="Read more" >...</a>

Tricuspid valve repair with the MitraClip technique

Current surgical and medical treatment options for severe tricuspid regurgitation are extremely limited. However, this historically forgotten valve seems to have the option of transcatheter repair, nowadays.   This observational study assessed the safety and feasibility of the MitraClip system for patients with severe chronic tricuspid regurgitation.   All patients presented severe tricuspid regurgitation and<a href="https://solaci.org/en/2017/04/27/tricuspid-valve-repair-with-the-mitraclip-technique/" title="Read more" >...</a>

Transcatheter Tricuspid Valve in valve

Original Title: Transcatheter Tricuspid Valve-in-Valve Implantation for the Treatment of Dysfunctional Surgical Bioprosthetic Valve. An International, Multicenter Registry Study. Reference: Doff B. McElhinney, et al. Circulation 2016;133:1582-93 Courtesy of Dr. Carlos Fava. Transcatheter tricuspid valve in valve implantation (TVIV) is infrequent, complex and biological valves last from 10 to 15 years. Reoperation is associated with high<a href="https://solaci.org/en/2016/04/21/transcatheter-tricuspid-valve-in-valve/" title="Read more" >...</a>